BR9909197A - Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv - Google Patents

Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv

Info

Publication number
BR9909197A
BR9909197A BR9909197-6A BR9909197A BR9909197A BR 9909197 A BR9909197 A BR 9909197A BR 9909197 A BR9909197 A BR 9909197A BR 9909197 A BR9909197 A BR 9909197A
Authority
BR
Brazil
Prior art keywords
alkyl
amino
alkyloxycarbonyl
mono
aryl
Prior art date
Application number
BR9909197-6A
Other languages
English (en)
Inventor
Frederik Frans Desire Daeyaert
Bart De Corte
Marc Rene De Jonge
Jan Heeres
Chih Yung Ho
Paul Adriaan Jan Janssen
Robert W Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9909197A publication Critical patent/BR9909197A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/48Two nitrogen atoms
    • C07D251/50Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/48Two nitrogen atoms
    • C07D251/52Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • C07D251/66Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • C07D251/70Other substituted melamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS 1,3,5-TRIAZINA TRI-SUBSTITUìDOS PARA O TRATAMENTO DE INFECçõES POR HIV"<D>. A presente invenção refere-se ao uso dos compostos de fórmula (I) os N-óxidos, os sais de adição farmaceuticamente aceitáveis e as formas estereoquimicamente isoméricas destes, onde A é CH, CR^ 4^ ou N; n é 0, 1, 2, 3, ou 4; R¹ e e R² são cada qual, independentemente selecionados dentre hidrogênio, hidróxi, C~ 1-12~ alquila, C~ 1-12~ alquilóxi, C~ 1-12~ alquilcarbonila, C~ 1-12~ alquiloxicarbonila, arila, amino, mono- ou di(C~ 1-12~ alquil)amino, mono- ou di(C~ 1-12~alquil)aminocarbonila, onde cada um dos grupos C~ 1-12~ alquila supramencionados, podem opcionalmente, e, individualmente ser substituídos; ou R¹ ou R² considerados juntos, podem formar pirrolidinila, piperidinila, morfolinila, azido ou mono- ou di(C~ 1-12~ alquil)amino-C~ 1-4~alquilideno; R³ é hidrogênio, arila, C~ 1-6~ alquilcarbonila, C~ 1-6~ alquila, C~ 1-6~ alquiloxicarbonila, C~ 1-6~ alquila substituída com C~ 1-6~ alquiloxicarbonila; e cada R~ 4~, independentemente, é hidróxi, halo, C~ 1-6~ alquila, C~ 1-6~alquilóxi, ciano, aminocarbonila, nitro, amino, trihalometila, ou trihalometilóxi; L é -X-R^ 5^ ou -X-Alq-R^ 6^, onde R^ 5^ e R^ 6^ são cada qual, independentemente, indanila, indolila ou fenila, cada um dos grupos indanila, indolila ou fenila podendo ser substituídos; e X é -NR^ 3^-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- ou -S(=O)~ 2~); arila é fenila opcionalmente substituído; Het é um radical alifático ou aromático heterocíclico opcionalmente substituído, para a produção de um medicamento para tratamento de indivíduos sofrendo de infecção por HIV (Vírus da Imunodeficiência Humana). A invenção refere-se ainda a novos compostos que são um subgrupo dos campostos de fórmula (I), à sua preparação e às composições farmacêuticas que os compreendem.
BR9909197-6A 1998-03-27 1999-03-24 Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv BR9909197A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7963398P 1998-03-27 1998-03-27
EP98201589A EP0945447A1 (en) 1998-03-27 1998-05-14 Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
PCT/EP1999/002044 WO1999050256A1 (en) 1998-03-27 1999-03-24 Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections

Publications (1)

Publication Number Publication Date
BR9909197A true BR9909197A (pt) 2000-12-05

Family

ID=22151790

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909197-6A BR9909197A (pt) 1998-03-27 1999-03-24 Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv

Country Status (33)

Country Link
US (3) US6150360A (pt)
EP (2) EP0945447A1 (pt)
JP (1) JP2002511390A (pt)
KR (1) KR100593396B1 (pt)
CN (1) CN1157386C (pt)
AP (1) AP1475A (pt)
AR (1) AR018169A1 (pt)
AT (1) ATE295355T1 (pt)
AU (1) AU758624C (pt)
BG (1) BG64903B1 (pt)
BR (1) BR9909197A (pt)
CA (1) CA2324921C (pt)
DE (1) DE69925256T2 (pt)
DK (1) DK1066269T3 (pt)
EA (1) EA004540B1 (pt)
EE (1) EE200000535A (pt)
ES (1) ES2243056T3 (pt)
HK (1) HK1032394A1 (pt)
HR (1) HRP20000621A2 (pt)
HU (1) HUP0101372A3 (pt)
ID (1) ID26043A (pt)
IL (1) IL138670A (pt)
NO (1) NO317425B1 (pt)
NZ (1) NZ506787A (pt)
OA (1) OA11493A (pt)
PL (1) PL194660B1 (pt)
PT (1) PT1066269E (pt)
SI (1) SI1066269T1 (pt)
SK (1) SK14052000A3 (pt)
TR (1) TR200002761T2 (pt)
TW (1) TW570917B (pt)
WO (1) WO1999050256A1 (pt)
ZA (1) ZA200006042B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
JP4919566B2 (ja) * 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
US6645964B1 (en) * 1999-11-29 2003-11-11 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agent
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU783981C (en) 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
US6858608B2 (en) * 2001-01-09 2005-02-22 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agents
US6887873B2 (en) * 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7163943B2 (en) * 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) * 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
PL369600A1 (en) * 2001-09-21 2005-05-02 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) * 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003032903A2 (en) * 2001-10-12 2003-04-24 New York University Trisubstituted triazines compounds with antitubulin activity
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
CN102151273B (zh) * 2002-02-05 2015-11-25 安斯泰来制药有限公司 2,4,6-三氨基-1,3,5-三嗪衍生物
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
WO2004074266A1 (en) * 2003-02-07 2004-09-02 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazines
US20070232572A1 (en) * 2003-02-07 2007-10-04 Aventis Pharma S.A. Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
US6875781B2 (en) * 2003-04-04 2005-04-05 Cell Therapeutics, Inc. Pyridines and uses thereof
US20060172010A1 (en) 2003-07-17 2006-08-03 Gael Lamoureux Process for preparing particles containing an antiviral
JP2006528640A (ja) * 2003-07-22 2006-12-21 ニューロジェン・コーポレーション 置換ピリジン−2−イルアミン類縁体
US7335770B2 (en) * 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
CN101035773B (zh) 2004-08-10 2012-06-06 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
TW200626560A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
TW200626561A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-substituted pyrimidines
TW200626574A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-heterocyclyl pyrimidines
RU2403254C2 (ru) 2004-10-29 2010-11-10 Тиботек Фармасьютикалз Лтд. Бициклические производные пиримидина, ингибирующие вич
US7592451B2 (en) * 2005-06-23 2009-09-22 New York University Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments
CN101245051B (zh) * 2005-12-22 2011-04-20 中国科学院上海药物研究所 2,4-二取代氨基-6-取代-[1,3,5]三嗪类化合物、其制备方法、药物组合物及用途
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
CN101573343B (zh) 2006-12-29 2016-02-24 爱尔兰詹森科学公司 抑制人免疫缺陷病毒的6-取代的嘧啶
CA2923637C (en) 2006-12-29 2018-10-02 Janssen Sciences Ireland Uc Hiv inhibiting 5,6-substituted pyrimidines
CN103476769B (zh) 2010-10-27 2016-06-01 沃尔特及伊莱萨霍尔医学研究院 抗癌剂
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9914709B2 (en) * 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
EP3122736A1 (en) * 2014-03-28 2017-02-01 Basf Se Diaminotriazine derivatives as herbicides
US10604492B2 (en) 2015-12-24 2020-03-31 The Regents Of The Universtiy Of California CFTR regulators and methods of use thereof
CN111629730A (zh) 2017-08-24 2020-09-04 加利福尼亚大学董事会 眼部药物组合物
CN109053613A (zh) * 2018-07-04 2018-12-21 复旦大学 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2742466A (en) * 1956-04-17 Chx n nhx c c
US2671810A (en) * 1952-05-24 1954-03-09 Du Pont Long-chain diketones
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4096206A (en) 1976-02-09 1978-06-20 Borg-Warner Corporation Flame-retardant triazines
US4652645A (en) 1983-11-16 1987-03-24 Ciba-Geigy Corporation Cationic compounds
EP0541966A3 (en) * 1991-11-15 1994-09-07 American Cyanamid Co Process for preparing amide derivatives from halomines and acid halides
US5283274A (en) * 1992-06-19 1994-02-01 Uniroyal Chemical Company, Inc. Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters
EP0723533A1 (en) 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
GB9519197D0 (en) * 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
CN1163401A (zh) * 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
CA2318362A1 (en) * 1998-01-13 1999-07-22 Sharon T. Cload Triazine antiviral compounds

Also Published As

Publication number Publication date
TW570917B (en) 2004-01-11
HUP0101372A2 (hu) 2001-10-28
CN1295566A (zh) 2001-05-16
JP2002511390A (ja) 2002-04-16
PT1066269E (pt) 2005-09-30
CN1157386C (zh) 2004-07-14
HUP0101372A3 (en) 2003-02-28
US20020115668A1 (en) 2002-08-22
NO317425B1 (no) 2004-10-25
US6150360A (en) 2000-11-21
EA200000993A1 (ru) 2001-04-23
WO1999050256A1 (en) 1999-10-07
ES2243056T3 (es) 2005-11-16
NO20004809L (no) 2000-11-24
ZA200006042B (en) 2001-10-26
DE69925256T2 (de) 2006-02-23
EP1066269B1 (en) 2005-05-11
SI1066269T1 (en) 2005-10-31
BG64903B1 (bg) 2006-08-31
NZ506787A (en) 2003-02-28
AR018169A1 (es) 2001-10-31
PL343195A1 (en) 2001-07-30
EP0945447A1 (en) 1999-09-29
ID26043A (id) 2000-11-16
EP1066269A1 (en) 2001-01-10
AU758624C (en) 2004-03-11
TR200002761T2 (tr) 2001-01-22
DK1066269T3 (da) 2005-09-05
AP1475A (en) 2005-10-03
BG104716A (en) 2001-04-30
EA004540B1 (ru) 2004-06-24
HRP20000621A2 (en) 2001-04-30
US6372729B1 (en) 2002-04-16
AU3599799A (en) 1999-10-18
ATE295355T1 (de) 2005-05-15
PL194660B1 (pl) 2007-06-29
DE69925256D1 (de) 2005-06-16
KR100593396B1 (ko) 2006-06-28
EE200000535A (et) 2002-04-15
IL138670A (en) 2005-12-18
CA2324921C (en) 2009-05-12
CA2324921A1 (en) 1999-10-07
OA11493A (en) 2004-05-07
SK14052000A3 (sk) 2001-06-11
HK1032394A1 (en) 2001-07-20
US6774235B2 (en) 2004-08-10
AP2000001913A0 (en) 2000-09-30
KR20010034270A (ko) 2001-04-25
AU758624B2 (en) 2003-03-27
NO20004809D0 (no) 2000-09-26

Similar Documents

Publication Publication Date Title
BR9909197A (pt) Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv
BR9909191A (pt) Derivados de pirimidina inibidores do hiv
BR9704937A (pt) Derivados de diamino-1,3,5-triazina substituìda
EA200000990A1 (ru) Вич-ингибирующие производные пиримидина
BRPI0407732A (pt) pirimidinas e triazinas inibidoras da replicação de hiv
BR9810097A (pt) Derivados de macrolìdeos c-4-substituìdos
MX9308016A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
ME00558A (en) Pyrazole derivatives for treating hiv
BRPI9810519B8 (pt) derivados de 4&#39;&#39;-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
ES2161418T3 (es) Compuestos de piridilfurano y de piridiltiofeno y uso farmaceutico de los mismos.
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BR9912729A (pt) Derivado de amida, processo para prepará-lo, e, uso do mesmo
HUP0104959A2 (hu) 4-Kinolinkarboxamid-származékok, előállításuk, neurokinin-2 (NK-2) és neurokinin-3 (NK-3) receptor antagonistákként történő felhasználásuk, valamint a vegyületeket tartalmazó gyógyszerkészítmények
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0408767B8 (pt) inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica
BR0315958A (pt) Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
ES2196332T3 (es) Derivados de hexahidro-pirido(4,3-b)indol como farmacos antipsicoticos.
ATE500231T1 (de) Hiv hemmende pyrimidin derivate
AR002264A1 (es) 6-[triazolil[3(trifluormetil)fenil]metil]-2-quinolinonas y quinolintionas, un procedimiento para su preparacion, una composicion que las comprende, unprocedimiento para su preparacion, el uso de las mismas para la preparacion de un medicamento y un intermediario.
BR9915176A (pt) Derivados de triazina dissubstituìdos nas posições 2,4
BR0314709A (pt) Derivados de pirazol
BR9811679A (pt) Antifúngicos de 1,3-dioxolanos 2,4,4-trissubstituìdos.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 251/70, C07D 251/52, C07D 403/12, C07D 251/42, C07D 251/50, C07D 251/66, A61K 31/53, A61P 31/18

Ipc: C07D 251/70 (2009.01), C07D 251/52 (2009.01), C07D

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements